| 109.881 |
Taxoid |
Aventis |
III |
| 572016 |
ErbB-2 and EGFR dual kinase inhibitor |
GlaxoSmithKline |
III |
| ABI-007 (paclitaxel) |
Taxane |
American Pharmaceutical Partners |
II/III |
| Abraxane |
Solvent-free nanoparticle albumin-bound taxane |
American Pharmaceutical Partners |
FDA Approval 01/05 |
| ABT 510 |
Synthetic peptide |
Abbott |
II |
| ABT 751 |
Antimitotic sulfonamide |
Abbott |
II |
| Advexin |
Gene therapy |
Introgen Therapeutics |
II |
| Alimta (pemetrexed sodium) |
Multi- targeted antifolate |
Eli Lilly |
II |
| AMD-473 |
Platinum |
AnorMed |
II |
| Angiozyme |
Anti angiogenic ribozyme |
Chiron |
II |
| Antiprogestin |
Hormonal |
Berlex |
I |
| APC 8024 |
HER2 antagonist |
Dendreon Corporation |
I |
| Aptosyn (exisuland) |
Selective apoptotic antineoplastic drug (SAAND) |
OSI Pharmaceuticals |
II |
| Arimidex (anastrozole) |
Aromatase agent |
AstraZeneca |
Approved and phase III |
| Aromasin (exemestane) |
Aromatase agent |
Pfizer |
Approved 10-05-05 |
| Atamestane |
Aromatase inhibitor |
BioMedicines |
III |
| Atrasentan |
Endothelial receptor agonist |
Abbott Laboratories |
II |
| AvastinÔ(bevacizumab) |
Anti-VEGF |
Genentech |
III |
| BMS-247550 |
Epithilone B analog |
Bristol-Myers Squibb |
II |
| Breast Cancer Vaccine |
Vaccine |
GlaxoSmithKline |
I |
| CDC 117 |
SERM |
Celgene |
I |
| CEA-Scan (arcitumomab) |
Radiolabeled antibody |
Immunomedics |
III |
| CEA-TRICOM |
Vaccine |
Therion Biologics |
I/II |
| CEA-Vac/Triab |
Vaccine |
Titan Pharmaceuticals |
III |
| CI-1033 |
Erb-b2 and EGFR dual kinase inhibitor |
Pfizer, NCI |
II |
| CP-724,714 |
HER2 inhibitor |
OSI Pharmaceuticals |
II |
| dendritic/cancer cell fusion |
Chemical fusion process |
Genzyme |
I/II |
| DENSPM (CI-1006, diethylnorspermine) |
Polyamine analog |
GelTex Pharmaceuticals |
II |
| Doxil (liposomal doxorubicin) |
Anthracycline |
Ortho Biotech |
III |
| E7070 |
Chloroindolyl- Sulfonamide |
Eisai |
II |
| Enhanzyn (adjuvant) |
Vaccine |
Corixa |
III |
| ERA 923 |
Anti-estrogen |
Ligand Pharmaceuticals |
II |
| ET-743 (yondelis) |
Marine derived antitumor agent |
Ortho Biotech |
II |
| Evista (raloxifene) |
SERM |
Eli Lilly |
III |
| Faslodex (fulvestrant) |
Selective estrogen receptor downregulator (SERD) |
AstraZeneca |
Approved and phase III |
| Femara (letrozole) |
Aromatase Agent |
Novartis |
Approved 12-29-05 ER/PR + Adjuvant |
| GEMÒ231 |
2nd generation antisense |
Hybridon |
I/II |
| GleevecÔ Imatinib mesylate |
Protein kinase inhibitor |
Novartis |
II |
| HER-2 autovac DNA |
Anti-Her2 vaccine |
Pharmexa |
I |
| HER2 neu vaccine |
Anti HER2 vaccine |
GlaxoSmithKline |
I |
| Herceptin (trastuzumab) |
Anti-HER2 monoclonal antibody |
Genentech, NCI |
Approved and phase III |
| H11 SCfV |
IgM monoclonal antibody |
Viventia Biotech |
I/II |
| Immu-102 (epratuzumab-Y-90) |
MoAb |
Immunomedics |
II |
| INGN 241 (mda7) |
Immune-stimulating and angiogenesis |
Introgen Therapeutics |
II |
| Iressa (gefitinib) |
EGFr Inhibitor |
Astra Zeneca |
II |
| ISIS 2503 |
Antisense therapy |
ISIS Pharmaceuticals |
II |
| Lasofoxifene |
SERM |
Pfizer |
III |
| MAC-321 |
Taxane |
Wyeth |
II |
| MDX-010 |
Antibody to the CTLA-4protein |
Medarex |
II |
| MS-209 |
Quinoline type MDR reversal |
Berlex |
II |
| MVA-MUC1-IL2 |
Gene therapy |
Transgene |
II |
| Omnitarg (Pertuzumab) |
HER2-directed monoclonal antibody |
Genentech, Roche |
II |
| Onconase (ranpirnase) |
Ribonuclease |
Alfacell |
II |
| OSI-7904L |
Liposomal encapsulated benzoquinazoline folate |
OSI |
I |
| Pipendoxifene |
|
Wyeth |
II |
| P53 and RAS vaccine |
Vaccine |
NCI |
I/II |
| PD-183805 |
Anti EGFR |
Pfizer |
II |
| PX—104.1 |
HER2 antagonist |
Pharmexa |
II |
| Perifosine |
Alkylphospholipids Anti AKT inhibitor |
AOI Pharmaceuticals |
II |
| R1550 |
Monoclonal antibody |
Roche |
I |
| Sarasar (lonafarnib) |
Oral Farnesyl Protein Transferase Inhibitor |
Schering-Plough |
I |
| SGN-15 |
Antibody-drug conjugate |
Seattle Genetics |
II completed |
| SR 31747 |
Peripheral sigma ligand |
Sanofi-Synthelabo |
II |
| Tarceva (erlotinib) |
EGF tyrosine kinase inhibitor |
Genentech, OSI Pharmaceuticals |
III |
| Targretin capsule |
Retinoid |
Ligand Pharmaceuticals |
II |
| Tariquidar |
P-glycoprotein antagonist |
QLT |
II |
| Taxoprexin (docosahexaenoic acid-paclitaxel) |
Taxane |
Protarga |
III |
| Taxotere (docetaxel) |
Taxoid |
Aventis |
Approved and phase III, II |
| Telcyta (TLK286) |
Selective apoptotic agent |
Telik |
II |
| temsirolimus (CCI-779) |
mTOR inhibitor |
Wyeth Pharmaceuticals |
II |
| Tesmilifene |
chemopotentiator |
YM BioSciences Inc. |
III |
| Theratope |
Vaccine |
Biomira |
III |
| VelcadeÔ(bortezomib) |
Proteosome inhibitor |
Millennium |
I |
| Xorax ( paclitaxel) |
Taxane |
IVAX |
II |
| Zarnestra (tipifarnib) |
Farnesyl transferase inhibitor |
Johnson & Johnson |
I/II |
Patient Home
Meeting Calendar
